Last reviewed 2026-05-14 · How we verify

IN-B001 Bivalent C dose

HK inno.N Corporation · Phase 1 active Biologic

IN-B001 Bivalent C dose is a Biologic drug developed by HK inno.N Corporation. It is currently in Phase 1 development.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	IN-B001 Bivalent C dose
Sponsor	HK inno.N Corporation
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity of High-dose IN-B001 in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IN-B001 Bivalent C dose CI brief — competitive landscape report
IN-B001 Bivalent C dose updates RSS · CI watch RSS
HK inno.N Corporation portfolio CI

Frequently asked questions about IN-B001 Bivalent C dose

What is IN-B001 Bivalent C dose?

IN-B001 Bivalent C dose is a Biologic drug developed by HK inno.N Corporation.

Who makes IN-B001 Bivalent C dose?

IN-B001 Bivalent C dose is developed by HK inno.N Corporation (see full HK inno.N Corporation pipeline at /company/hk-inno-n-corporation).

What development phase is IN-B001 Bivalent C dose in?

IN-B001 Bivalent C dose is in Phase 1.

Manufacturer: HK inno.N Corporation — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing